<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013139</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU2314</org_study_id>
    <nct_id>NCT04013139</nct_id>
  </id_info>
  <brief_title>Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)</brief_title>
  <official_title>Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reductions in exercise capacity associated with exercise intolerance augment cardiovascular
      disease risk and predict mortality in chronic kidney disease. This study utilized
      cardiopulmonary exercise testing to (a) investigate mechanisms of exercise intolerance; (b)
      unmask subclinical ca and p and vitamin D abnormalities that may precede cardiovascular
      disease in chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiopulmonary exercise testing will carry out in Stage 3-5 chronic kidney disease patients
      ; estimated glomerular filtration rate &lt;60 ml/min/1.73 m2) and biochemistry will be added (Ca
      P Via D PTH FGF23).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calcium x phosphorus change in stage 3-5</measure>
    <time_frame>12 MONTHS</time_frame>
    <description>CaxP change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CPET score change</measure>
    <time_frame>12 MONTHS</time_frame>
    <description>Evaluation of CPET score change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function change</measure>
    <time_frame>12 MONTHS</time_frame>
    <description>GFR change</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ckd-Mbd</condition>
  <arm_group>
    <arm_group_label>CKD Stage 3</arm_group_label>
    <description>CKD patients with GFR between 30-60cc/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD Stage 4</arm_group_label>
    <description>CKD Patients with GFR 15-30 cc/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CPET</intervention_name>
    <description>CPET</description>
    <arm_group_label>CKD Stage 3</arm_group_label>
    <arm_group_label>CKD Stage 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All &gt;18 years CKD Patients with GFR &lt;60 non-dialysis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD Patients with GFR &lt;60 non-dialysis

          -  age&lt;18

        Exclusion Criteria:

          -  HTN

          -  not signing consent

          -  active coronary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalili</last_name>
    <role>Principal Investigator</role>
    <affiliation>SBMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nooshin Principal Investigator</last_name>
    <phone>00989122404331</phone>
    <email>nooshindalili4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nooshin Dalili</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nooshin Dalili, Dr</last_name>
      <phone>00989122404331</phone>
      <email>nooshindalili4@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>nooshin dalili</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

